Stock Events

Stock Events

Pharmamar. 

€92.95
0
+€1.2+1.31% Today

Statistics

Day High
94.3
Day Low
92.8
52W High
100
52W Low
70.2
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMRA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that develops medications in areas similar to Pharmamar, including oncology, making it a direct competitor in the cancer treatment market.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb operates in the biopharmaceutical industry focusing on cancer, a key area for Pharmamar, making them competitors in developing and commercializing oncology treatments.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a large pharmaceutical company with a broad product line that includes oncology treatments, competing with Pharmamar in the cancer drug market.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC focuses on the discovery, development, and commercialization of prescription medicines, including those for cancer, directly competing with Pharmamar in the oncology sector.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is known for its innovative therapies in areas like oncology, directly competing with Pharmamar in the development of cancer treatments.
Novartis
NVS
Mkt Cap297.32B
Novartis AG operates globally in the pharmaceutical sector, with a strong emphasis on oncology, making it a competitor to Pharmamar in the cancer treatment market.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG focuses on pharmaceuticals and diagnostics with a strong portfolio in oncology, competing with Pharmamar in cancer treatment innovations.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. is a biotechnology company focusing on human therapeutics, including oncology, which puts it in direct competition with Pharmamar in the biopharmaceutical sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for serious medical conditions, including cancer, making it a competitor to Pharmamar.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson operates in the pharmaceutical and healthcare sectors, with a focus on developing treatments for various diseases, including cancer, positioning it as a competitor to Pharmamar in the healthcare market.

About

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Show more...
CEO
Mr. Jose Maria Fernandez Sousa-Faro
Employees
477
Country
Spain
ISIN
ES0169501022

Listings

STU
DE
PMRA.STU
VI
AT
PHM.VI
LSE
GB
0RC6.LSE
F
DE
PMRA.F

0 Comments

Share your thoughts

FAQ

What is Pharmamar. stock price today?▼
The current price of PMRA.STU is €92.95 EUR — it has increased by +1.31% in the past 24 hours. Watch Pharmamar. stock price performance more closely on the chart.
What is Pharmamar. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharmamar. stocks are traded under the ticker PMRA.STU.
Is Pharmamar. stock price growing?▼
PMRA.STU stock has risen by +2.14% compared to the previous week, the month change is a +12.81% rise, over the last year Pharmamar. has showed a +13.92% increase.
How many employees does Pharmamar. have?▼
As of April 10, 2026, the company has 477 employees.
In which sector is Pharmamar. located?▼
Pharmamar. operates in the Healthcare sector.
When did Pharmamar. complete a stock split?▼
Pharmamar. has not had any recent stock splits.
Where is Pharmamar. headquartered?▼
Pharmamar. is headquartered in Madrid, Spain.